77533-18-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromomethyl-3-Chlorobenzonitrile is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drugs with specific therapeutic properties, making it an essential component in drug development processes.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromomethyl-3-Chlorobenzonitrile is employed as an intermediate for the production of pesticides and other agrochemicals. Its contribution to the development of effective and targeted agrochemicals aids in enhancing crop protection and yield.
Used in Organic Synthesis:
2-Bromomethyl-3-Chlorobenzonitrile serves as a versatile building block in organic synthesis, enabling the construction of a broad range of organic molecules. Its reactivity and structural features facilitate the synthesis of complex organic compounds for various applications.
Used in Material Science:
In the field of material science, 2-Bromomethyl-3-Chlorobenzonitrile is leveraged in the development of new materials with specific properties. Its integration into material compositions can lead to advancements in areas such as polymers, coatings, and specialty chemicals.

InChI:InChI=1/C8H5BrClN/c9-4-7-6(5-11)2-1-3-8(7)10/h1-3H,4H2

Upstream product

• 54454-12-5 (3-chloro-2-methylphenyl)carbonitrile 

Relevant academic research and scientific papers

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

THERAPEUTIC PYRROLIDINES

The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.

ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED INDOLE OR DIHYDROINDOLE

Substituted heterocycles attached through a methylene bridge to novel substituted indole or dihydroindole derivative of the Formula I are useful as angiotensin II antagonists. STR1

ANGIOTENSIN II ANTAGONISTS INCORPORATING AN INDOLE OR DIHYDROINDOLE

There are disclosed substituted indoles and dihydroindoles of Formula I which are useful as angiotensin II antagonists. STR1

1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives

Derivatives of 1,3-dihydro-3-(2-hydroxyethyl) -2H-isoindol-1-one are disclosed. The derivatives are useful for treating ulcers in a mammal and for preventing or decreasing the secretion or availability of excessive amounts of gastric or hydrochloric acid in a mammal suffering from hyperchlorhydria and/or associated conditions.